Table 2 Clinical data of gastric cancer patient-derived organoids.
From: Establishment of gastric signet ring cell carcinoma organoid for the therapeutic drug testing
Patient ID | Sex | Age | Diagnosis | TNM (UICC stage) | Tumor differentiation | Histology (Lauren classification) | Tumor site |
|---|---|---|---|---|---|---|---|
G01 | M | 56 | Adenocarcinoma | T4aN3bM0 (IIIC) | Poor | Diffuse | Antrum |
G04 | F | 70 | Adenocarcinoma | T4aN3bM0 (IIIC) | Poor | Mixed | Cardia |
G06a | F | 55 | Adenocarcinoma | T1aN0M0 (IA) | Poor | Diffuse | Body |
G08 | F | 66 | Adenocarcinoma | T2aN3bM1(IV) | Moderate | Mixed | Body |
G10 | F | 69 | Adenocarcinoma | T4N3aM0 (IIIA) | Poor | Intestinal | Body |
G14 | F | 56 | Adenocarcinoma | T4N3aM0 (IIIA) | High | Intestinal | Cardia |
G16 | F | 69 | Adenocarcinoma | T4aN3aM0 (IIIB) | Moderate | Mixed | Cardia |
G18 | F | 56 | Adenocarcinoma | T4aN3aM0 (IIIB) | Moderate | Intestinal | Antrum |
G20a | F | 48 | Adenocarcinoma | T4aN3aM0 (IIIB) | Poor | Diffuse | Body |
G22a | M | 58 | Adenocarcinoma | T4aN2M0(IIIA) | Poor | Diffuse | Body |
G23 | M | 47 | Adenocarcinoma | T4aN3aM0 (IIIB) | Poor | Diffuse | Body |
G25a | F | 55 | Adenocarcinoma | T3NM0(IIA) | Poor | Diffuse | Cardia |
